Clinical Evidence: How Sucralfate Physically Shields Ulcers from Stomach Acid

Learn why Clinical Evidence: How Sucralfate Physically Shields Ulcers from Stomach Acid is drawing attention with our thorough coverage.

The primary, FDA-approved indication for sucralfate remains the short-term treatment and maintenance of active duodenal ulcers. In randomized clinical evaluations, a four- to eight-week regimen produces complete healing rates ranging between 75% and 82%, rivaling the efficacy of chemical acid suppressors.

Physicians frequently turn to sucralfate for clinical problems beyond duodenal ulcers, relying on both tablet and suspension forms:

• Stomach Ulcers (Gastric Ulcers): While healing rates can be slightly lower than those seen in the duodenum due to higher shear stress inside the stomach antrum, the drug offers critical mucosal protection when NSAID damage is present.
• Gastroesophageal Reflux Disease (GERD): Standard acid reducers lower the acidity of refluxate, but they do not stop non-acidic digestive enzymes or bile salts from scorching the esophagus. Sucralfate oral suspension coats the esophageal lining, protecting patients suffering from refractory nighttime reflux or bile reflux.
• Radiation-Induced Mucositis and Proctitis: Oncologists utilize sucralfate suspensions as topical rinses or retention enemas to protect mucosal surfaces damaged during radiation therapy for head, neck, and pelvic cancers.
• In intensive care units, ventilated patients frequently receive sucralfate because it protects the gastric lining against stress ulcers without raising gastric pH, which reduces the risk of nosocomial pneumonia linked to bacterial colonization of neutralized stomachs.